Liraglutide

Active substance
Liraglutide
Domain
Metabolism and Endocrinology
Reason of inclusion in Horizonscan Geneesmiddelen
Indication extension
Main indication
Other metabolism and Endocrinology
Extended indication
Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with body weight above 60 kg and obesity (BMI corresponding to ≥30 kg/m2 for adults).

1. Product

Proprietary name
Saxenda
Manufacturer
Novo Nordisk
Mechanism of action
GLP-1 receptor agonist
Route of administration
Subcutaneous
Therapeutical formulation
Injection
Budgetting framework
Extramural (GVS)
Additional comments
GLP-1 analoog

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
February 2020
Expected Registration
January 2021
Orphan drug
No
Registration phase
Registration application pending

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
1 times a day
References
NCT02918279

4. Expected patient volume per year

There is currently nothing known about the expected patient volume.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.